BPC-157 is one of the most discussed peptides on the wellness internet and one of the least documented in the human clinical literature, and the gap between those two facts is where most of its safety story sits.

The compound has been studied in laboratories for more than thirty years. It has been studied in humans for almost none of them. Roughly 200 papers on BPC-157 are listed on PubMed; nearly all of them come from a single research group at the University of Zagreb in Croatia. The compound has never been the subject of a completed Phase III human clinical trial. It is not approved as a medicine in any country. It is prohibited by the World Anti-Doping Agency for any athlete subject to drug testing. And in April 2026, after almost three years of regulatory limbo, the US Food and Drug Administration removed BPC-157 from its list of bulk drug substances flagged for significant safety concerns. The removal did not resolve the underlying safety questions. It happened because the nominators withdrew their submissions before the agency was forced to rule on them.

That is the regulatory backdrop. The clinical backdrop is what follows.

Where BPC-157 actually came from

BPC-157 stands for Body Protection Compound-157. It is a synthetic fragment of a larger protein that occurs naturally in human gastric juice. The fragment is fifteen amino acids long. It was first isolated and characterised by Professor Predrag Sikiric and his research group at the University of Zagreb in the early 1990s, with the foundational paper published in the Journal of Physiology (Paris) in 1993.

Dr Adrijana Kekic, a Doctor of Pharmacy and faculty member at the Geneva College of Longevity Sciences, was at the University of Zagreb when the discovery happened.

“BPC 157 is a compound that was really discovered in […] gut,” Kekic says. “All of us in a way make this compound. So it’s a naturally occurring compound more or less. It has been produced by gut. And what we know is it can really aid in repair, healing, reducing inflammation, [and a] bunch of other things that tend to be associated [with] these hallmarks of aging.”

Kekic spent more than a decade at the Mayo Clinic as one of the first pharmacogenomic clinical pharmacy specialists in the United States. She now lectures on peptide compounding practice, including, in her own words, “good practices versus red flag practices.” She is unusual among clinicians publicly discussing BPC-157 in that she has known the people who discovered it.

The Zagreb origin story is one piece of context the wellness market tends to skip. The other piece is the structure of the published evidence. A February 2026 investigation by Undark established that the overwhelming majority of BPC-157 studies on PubMed include either Sikiric or his colleague Sven Seiwerth as a main author. The research base is, in effect, the output of one laboratory and its collaborators over thirty years. That is not in itself a flaw. Sikiric’s group has done foundational work the field would not otherwise have. But it is the reason independent replication is the gap the rest of the literature has not yet filled.

What the research base contains, and what it doesn’t

Almost everything published on BPC-157 is preclinical. The animal data, primarily in rats, suggests the peptide may accelerate healing in tendons, ligaments, muscles and the gastrointestinal lining; reduce inflammation; promote angiogenesis (the formation of new blood vessels); and protect tissue against various forms of induced damage.

The most recent comprehensive synthesis is a July 2025 systematic review in the HSS Journal, the musculoskeletal journal of the Hospital for Special Surgery in New York, led by Nikhil Vasireddi at Case Western Reserve University School of Medicine. The review screened 544 articles. Its conclusion was that preclinical evidence supports BPC-157’s potential in musculoskeletal healing but that human clinical data remains “extremely limited.” The review notes that BPC-157 is “increasingly used by clinicians and athletes” despite the absence of FDA approval and the WADA ban.

What “increasingly used” looks like in practice is private clinics, compounding pharmacies, and the research-chemical market. These are channels that sit outside the regulatory and reporting systems that would generate the human safety data the literature is missing.

Dr Neil Paulvin, a functional medicine practitioner who works with peptides, describes what he sees in his own practice. It is anecdotal rather than trial-grade data, but clinically observed:

“I’ve had patients with colonoscopies for gut conditions — whether it’s irritable bowel or, more commonly, Crohn’s or ulcerative colitis, which are often autoimmune-related,” Paulvin says. “They’ll have ulcers or inflammation. And then three to six months later, they go back in and the gastroenterologist says, ‘Your gut is healing really well — I’ve never seen this before.’ So it can be a clear A-to-B case. Other times, you’re guesstimating a bit. But usually, we have a decent idea of what’s working and what’s not.”

The mechanistic logic for gut effects has a known route. Most peptides are destroyed in the digestive system, which is why injectable forms dominate the market. BPC-157 appears to be unusually stable in gastric juice, which is the basis for the oral formulations available in the research-chemical market.

“[If] you’re taking it orally, we know that peptides are not going to survive,” Kekic says. “Most of them don’t survive the hostile environment of our gut. But perhaps for some of those peptides that actually need to make it to your gut and stay there as opposed to be systemically absorbed and delivered through your body, it’s okay that they are there.”

For musculoskeletal indications (tendons, ligaments, joints), the route is subcutaneous injection near the site of injury. The Vasireddi review surveys the case-report literature on these uses; the number of published human cases is small.

The safety picture: what has been reported, what is unknown, who should not take it

The reported side-effect profile of BPC-157 is built almost entirely on anecdote, animal data, and clinician observation. There are no large-scale human safety trials. What has been documented from these sources includes:

• Headaches, typically described as dull and short-lived
• Dizziness or light-headedness, particularly after injection
• Nausea or mild digestive discomfort, more common with oral forms
• Injection-site reactions including redness, swelling and irritation
• Appetite changes, sometimes reported as increased hunger
• Disrupted sleep when dosed in the evening
• Less commonly, palpitations or mood changes

None of these has been formally linked to BPC-157 in peer-reviewed human studies. They are reported by users and observed by clinicians; the literature has not yet caught up to either.

The more important safety question is the one the consumer pages tend to gesture at without naming clearly. BPC-157 promotes angiogenesis: the formation of new blood vessels. Angiogenesis is also one of the processes that allows tumours to grow. The animal evidence has not shown BPC-157 to be carcinogenic; the Sikiric group has consistently argued the opposite. But the population of people who have taken BPC-157 outside research settings has not been followed for the kind of duration that would resolve the question, and Kekic is unambiguous about what that means for her clinical practice.

“I would probably use caution with the majority of peptides,” she says. “If you have an active cancer, you are not a good candidate for these. If you have a predisposition and you are under a lot of stress where those cancer cells really can start to grow, especially if you’re using a high protein diet that is really high amounts of methionine amino acid […] I would be very cautious.”

It is the single clearest contraindication a clinician has articulated on the record for BPC-157. People with active cancer, recent cancer history, or known cancer predispositions are not candidates for the peptide.

The second safety question is the supply chain. Because BPC-157 is not approved for human use in any major jurisdiction, the product that consumers actually take is produced by chemical synthesis companies operating outside pharmaceutical regulation. Purity, sterility, and the absence of endotoxins are not guaranteed in the same way they would be for a licensed medicine.

Dr Dan Reardon, a UK A&E physician who sees peptide-related cases in emergency departments, frames it as a basic-rigour problem.

“When it comes to safety, I am of the belief that anything that we give to somebody, there should be the right levels of safety,” Reardon says. “We should know where the product’s coming from, how it’s been manufactured, how it’s been imported, just some of the basic stuff. And the thing with peptides is compounding facilities are getting closed around the world left, right and centre. So we don’t have that same sort of rigour, if you like, on just overall safety.”

The third safety question is legal, and the answer differs by jurisdiction:

• United States. BPC-157 is not FDA-approved for any indication. In September 2023, the FDA placed it in Category 2 of its interim 503A bulks list: the list of substances flagged for significant safety concerns that could not be used by compounding pharmacies. In April 2026, the FDA removed BPC-157 from Category 2 after the nominators withdrew their submissions. The agency has scheduled a Pharmacy Compounding Advisory Committee review for July 2026 to determine whether BPC-157 will be permitted on the 503A bulks list. Until that review concludes and is implemented at state level, the compounding position is in transition.
• United Kingdom. BPC-157 is an unlicensed medicine. The Medicines and Healthcare products Regulatory Agency has not approved it for any clinical use, and it cannot lawfully be marketed for human consumption, sold as a supplement, or prescribed on the NHS. It can be sold as a research chemical labelled “for research purposes only / not for human consumption.” This is a legal grey area rather than a clear permission.
• Athletes. The World Anti-Doping Agency added BPC-157 to its Prohibited List in January 2022 under category S0 (Non-Approved Substances). It is prohibited at all times, in and out of competition, with no Therapeutic Use Exemption pathway available. Athletes subject to WADA, USADA, NCAA, or equivalent testing cannot use BPC-157 in any form.

Why response varies

The variability of reported responses to BPC-157 is one of the recurring features of the consumer discussion. Some people report dramatic recovery from injuries that had not previously healed; others report nothing. Kekic offers a framing for this from her clinical practice.

“Those folks who tend to have more optimised soil, meaning internal environment, tend to respond better to those peptides than folks who have [a] variety of either preconditions, meaning they’re not diagnosed yet, or actual conditions of diseases that are diagnosed,” she says. “If you have a very strong inflammatory, systemic inflammatory signal, it’s very difficult for that little small molecule like BPC-157 or peptides in general to make a significant impact when your soil is disrupted.”

The framing is informally clinical rather than peer-reviewed, but it lines up with what the Vasireddi review describes as the literature’s current state: signals of effect in defined research conditions, inconsistent translation to the heterogeneous population of real-world users.

The wellness market sells BPC-157 as a fix. The clinical literature, where it exists, suggests it might be a small additional input in a body that is otherwise already well looked after. That distinction is not currently being made on most of the websites selling the compound.

Until human clinical trials (the kind the FDA’s July 2026 PCAC consultation is partly designed to assess the case for) produce safety and efficacy data in actual populations of users, the gap between what BPC-157 might do and what is documented that it does in people remains the most important thing to understand about it.